Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Tetracycline biosimilars are derived from tetracycline antibiotics, which are known for their diverse structures and broad-spectrum antibacterial activity. These antibiotics have been in clinical use for over seven decades, with continuous contributions to human health. The biosynthesis of tetracycline involves complex pathways that produce various natural products with remarkable bioactivities. Tetracycline biosimilars, such as eravacycline and omadacycline, have unique chemical structures that help them retain activity against bacteria with tetracycline-specific resistance mechanisms. These biosimilars are effective against a wide range of bacterial infections, although they lack activity against Pseudomonas species. The development of tetracycline biosimilars focuses on enhancing their efficacy and overcoming resistance, ensuring their continued relevance in medical treatments.
仅用于科研。不用于诊断过程。未经明确授权不得转售。